NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy
Executive Summary
The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.
You may also be interested in...
NeuroPace Seeks $75M In IPO
The California neuromodulation company filed a registration with the US Securities and Exchange Commission to sell common stock on NASDAQ under the ticker NPCE.
NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.
News We're Watching: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients
This week, studies supported Nevro’s spinal cord stimulation therapy and a VRx system that helps reduce pain; the American Medical Association found inconsistent insurance coverage of digital therapeutics; and Geneticure announced a cheek-swab test to identify which patients are most likely to benefit from renal denervation.